Skip to main content

Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice

Supportive Care in Cancer volume 16, pages 485–491 (2008)Cite this article

Abstract

Goals of work

Febrile neutropenia (FN) represents a spectrum of severity in which low-risk patients can be defined using the Multinational Association for Supportive Care in Cancer (MASCC) risk index. However, despite publication in 2000, there remains limited published literature to date to support the use of MASCC risk assessment in routine clinical practice and eligibility for early hospital discharge. In this study, we present our experience with the routine use of the MASCC risk index to determine the management of FN in our institution.

Patients and methods

Patients treated for solid tumours or lymphomas with low-risk FN (MASCC score ≥21) were eligible for oral antibiotics (ciprofloxacin plus either co-amoxiclav or doxycycline) and for early hospital discharge irrespective of first or subsequent episode. The primary outcome was rate of resolution of FN without serious medical complications (SMC). Secondary outcomes were the “success” of antibiotic therapy without treatment modifications, duration of hospitalisation and rate of readmissions.

Results

A total of 100 FN episodes occurring in 83 patients were treated over a 6-month period. Ninety of these episodes were low-risk (90%), of which 75 received oral antibiotics (83.3%) and 3 (3.3%) experienced SMC, and the success rate was 94.5% [95% confidence interval (CI) 89.6–99.3%] in low-risk episodes. The median duration of hospitalisation was 2.5 days (25th centile: 1.0 day; 75th centile: 5.0 days) in low-risk compared to 6.5 days (25th centile: 5.3 days; 75th centile: 9.3 days) in high-risk episodes (p = 0.003); 2 days for low-risk episodes treated with oral antibiotics compared to 4 days for low-risk receiving intravenous antibiotics (p = 0.015). Positive predictive value for the MASCC index was 96.7% (95% CI 95.0–98.6%).

Conclusion

The MASCC risk index is both feasible and safe when used in standard clinical practice to guide the management of FN in patients with solid tumours and lymphomas. Patients predicted to have low risk can be managed safely with oral antibiotics and early hospital discharge.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Elting LS, Rubenstein EB, Rolston KV, Bodey GP (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25:247–259

    PubMed  Article  CAS  Google Scholar 

  2. Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, Hiemenz S, Hicks JE, Gill V, Steinberg SM, Pizzo PA (1999) A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341:305–311

    PubMed  Article  CAS  Google Scholar 

  3. Innes HE, Smith DB, O’Reilly SM, Clark PI, Kelly V, Marshall E (2003) Oral Antibiotics with early discharge compared with in-patients intraveneous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomized controlled single center study. Br J Cancer 89(1):43–49

    PubMed  Article  CAS  Google Scholar 

  4. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 341:312–318

    PubMed  Article  CAS  Google Scholar 

  5. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051

    PubMed  CAS  Google Scholar 

  6. Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, Lalami Y, Aoun M, Barette M (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129–4134

    PubMed  Article  CAS  Google Scholar 

  7. Marshall E, Smith DB, O’Reilly SM, Murray A, Kelly V, Clark PI (2000) Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients. Support Care Cancer 8:198–202

    PubMed  Article  CAS  Google Scholar 

  8. Paesmans M, Rapoport B, Maertens J, Slabbeer C, Ferrant A, Wingard J, Aoun M, Dubreucq L, Plehiers B, Klastersky J (2003) Multicentric prospective validation of the MASCC risk-index score for identification of febrile neutropenic cancer patients at low-risk for serious medical complications. Proc Am Soc Clin Oncol 22:2235

    Google Scholar 

  9. Rubin M, Hathorn JW, Pizzo PA (1988) Controversies in the management of febrile neutropenic cancer patients. Cancer Invest 6:167–184

    PubMed  Article  CAS  Google Scholar 

  10. Talcott JA, Finberg R, Mayer RJ, Goldman L (1988) The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148:2561–2568

    PubMed  Article  CAS  Google Scholar 

  11. Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322

    PubMed  CAS  Google Scholar 

  12. Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive care of Cancer (MASCC) risk-index score. Support Care Cancer 8:556–560

    Google Scholar 

  13. Viscoli C, Bruzzi P, Castagnola E, Boni L, Calandra T, Gaya H, Meunier F, Feld R, Zinner S, Klastersky J (1994) Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 30A:430–437

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clatterbridge Centre for Oncology NHS Foundation Trust, Bebington, Wirral Merseyside, CH63 4JY, UK

    Helen Innes, Sheow Lei Lim, Allison Hall, Su Yin Chan, Neeraj Bhalla & Ernest Marshall

Authors
  1. Helen Innes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheow Lei Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Allison Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Su Yin Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Neeraj Bhalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ernest Marshall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ernest Marshall.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Innes, H., Lim, S.L., Hall, A. et al. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer 16, 485–491 (2008). https://doi.org/10.1007/s00520-007-0334-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-007-0334-8

Keywords

  • MASCC risk index
  • Low-risk febrile neutropenia
  • Oral antibiotics